Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Betamethasone Dipropionate Nasal Cream for eCRS
NCT05220293Phase 2Terminated
- Sponsor
- Oticara
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of betamethasone dipropionate spray 0.05% in eosinophilic chronic rhinosinusitis (ECRS), sponsored by Oticara. Started Feb 2022; status: terminated.
02
Drugs
betamethasone dipropionate spray 0.05%
03
Conditions
eosinophilic chronic rhinosinusitis (ECRS)
Beyond the preview
Go deeper on NCT05220293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220293.